Answers are grounded in this paper and cite their sources.
Quasi-experimental trial found Dienogest reduces EAPP scores in women, indicating effective pain relief.
Endometriosis is a chronic, estrogen-dependent condition affecting women of reproductive age, with peak incidence between 25 and 30 years. Dienogest 2 mg daily has been shown to effectively relieve endometriosis-related pain, reduce endometriotic lesions, and improve quality of life. A quasi-experimental trial at Shifa International Hospital, Islamabad, over 12 months assessed the efficacy of Dienogest 2 mg daily for managing endometriosis-associated pelvic pain (EAPP). The study involved 105 women with a mean age of 28.3 years and a mean BMI of 26.2. EAPP was measured using the Visual Analogue Scale (VAS) at baseline, 3 months, and 6 months. Results indicated a significant reduction in VAS scores from 7.12 at baseline to 4.50 at 3 months and 2.62 at 6 months, demonstrating a clinically meaningful improvement in pain levels.
No takes yet. Share an insight, caveat, or question.
Sajida et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: